cyclohexanol has been researched along with fluoxetine in 222 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 45 (20.27) | 18.2507 |
| 2000's | 110 (49.55) | 29.6817 |
| 2010's | 65 (29.28) | 24.3611 |
| 2020's | 2 (0.90) | 2.80 |
| Authors | Studies |
|---|---|
| Preskorn, SH | 2 |
| Jaffe, IA | 1 |
| Althof, SE | 1 |
| Clerc, GE; Ruimy, P; Verdeau-Pallès, J | 1 |
| Feighner, JP | 1 |
| Dierick, M; Martin, A; Ravizza, L; Realini, R | 1 |
| Castañeda, R; Levy, R; Sussman, N; Westreich, LM | 1 |
| Möller, HJ; Volz, HP | 1 |
| Ahern, D; Ball, SE; Kao, J; Scatina, J | 1 |
| Benazzi, F | 4 |
| Adès, J; Lejoyeux, M | 1 |
| Haddad, P | 1 |
| Mitchell, S; Tracy, KA; Zajecka, J | 1 |
| Jaffe, IA; Rudikoff, D | 1 |
| Heal, DJ; Hutchins, LJ; Jackson, HC; Mazurkiewicz, SE; Needham, AM | 1 |
| Richelson, E | 2 |
| Gorman, JM | 1 |
| Amsterdam, JD; Garcia-España, F; Goodman, D; Hooper, M; Hornig-Rohan, M | 1 |
| Bhatara, VS; Magnus, RD; Paul, KL; Preskorn, SH | 1 |
| Coupland, NJ; Zedkova, L | 1 |
| Béïque, JC; de Montigny, C; Debonnel, G; Lavoie, N | 1 |
| Dogin, JW; Findling, RL | 1 |
| Costa e Silva, J | 1 |
| Mitchell, PJ; Redfern, PH | 1 |
| Archer, SL; Nelson, DP; Reeve, HL; Weir, EK | 1 |
| Ravindran, A; Silverstone, PH | 1 |
| Ferrier, IN | 1 |
| Bakish, D | 1 |
| Altenburg, SP; da-Silva, VA; Lindsey, CJ; Malheiros, LR; Thomaz, TG | 1 |
| Michelson, D | 1 |
| Chong, Y; Harris, R; Kim, WJ | 1 |
| Boyer, P | 1 |
| Peretti, CS | 1 |
| Thase, ME | 1 |
| Paton, C | 1 |
| Judge, R; Wagner, BE | 1 |
| Alfaro, CL; Ereshefsky, L; Lam, YW; Simpson, J | 1 |
| Blanco, C; Mullen, LS; Roose, SP; Vaughan, R; Vaughan, SC | 1 |
| Feiger, AD; Rudolph, RL | 1 |
| Cabras, PL; Cellini, M; Di Bernardo, M; Mannucci, E; Paionni, A; Ricca, V; Rotella, CM | 1 |
| Anisman, H; Griffiths, J; Merali, Z; Ravindran, AV; Zaharia, MD | 1 |
| Hatanaka, K; Yamaguchi, T; Yatsugi, S | 2 |
| Dunn, NR; Freemantle, SN; Mackay, FR; Mann, RD; Martin, RM; Pearce, GL | 1 |
| Guazzelli, M; Nimatoudis, I; Rizzo, F; Smeraldi, E; Tzanakaki, M; Zissis, NP | 1 |
| Elie, R; Habimana, A; Hébert, C; Reader, TA | 1 |
| Deslandes, PN; Pache, DM; Sewell, RD; Subhan, F | 1 |
| Woods, SW | 1 |
| Fitzgerald, F; Glod, CA; Lynch, A | 1 |
| Gorman, JM; Nierenberg, AA; Stahl, SM | 1 |
| Bosmans, E; Kenis, G; Kubera, M; Lin, AH; Maes, M; van Bockstaele, D | 1 |
| Cook, IA; Leuchter, AF | 1 |
| Albano, D; Amchin, J; Ereshefsky, L; Klockowski, PM; Taylor, K; Zarycranski, W | 1 |
| Hibberd, C; Noble, J; Seckl, JR; Yau, JL | 1 |
| Nierenberg, AA | 1 |
| Salinas, E; Silverstone, PH | 1 |
| Dagge, A; Holzinger, J; Hornik, L; Körfer, R; Minami, K; Mirow, N; Schulz, U; Tenderich, G | 1 |
| Perry, CM; Wellington, K | 1 |
| Judge, R | 1 |
| Cheng, CY; Hong, CJ; Huo, SJ; Tsai, SJ; Wu, WH | 1 |
| Abrams, M; Cook, IA; Leuchter, AF; Morgan, M; Witte, EA | 1 |
| Entsuah, AR; Huang, H; Thase, ME | 1 |
| Baker, GB; Kennedy, SH; Masellis, M; McCann, SM; McIntyre, RS; McKay, G; Raskin, J | 1 |
| Abrams, M; Cook, IA; Leuchter, AF; Morgan, M; Rosenberg, S; Stubbeman, WF; Uijtdehaage, SH; Witte, E | 1 |
| Audia, JE; Katofiasc, MA; Nissen, J; Thor, KB | 1 |
| De Bleeker, E; De Nayer, A; Evrard, JL; Fossion, P; Geerts, S; Leyman, S; Linkowski, P; Mignon, A; Ruelens, L; Schittecatte, M; Van Eeckhoutte, I | 1 |
| Cantillon, M; Davidson, JR; Hackett, D; Haudiquet, V; Meoni, P | 1 |
| Entsuah, R; Rudolph, RL; Stahl, SM | 1 |
| Beyer, CE; Boikess, S; Dawson, LA; Luo, B | 1 |
| Dawson, LA; Li, P | 1 |
| Calleri, E; Cherkaoui, S; Geiser, L; Prat, J; Rudaz, S; Veuthey, JL | 1 |
| Amsterdam, JD; Brunswick, DJ | 1 |
| Goetz, MP; Loprinzi, CL | 1 |
| Cheng, KT; DeVane, CL; Donovan, JL; Liston, HL; Markowitz, JS; Risch, SC; Willard, L | 1 |
| Fontes, CL; Geissler, EC; Harada, AS; Wan, GJ; Yu-Isenberg, KS | 1 |
| Basta-Kaim, A; Bosmans, E; Budziszewska, B; Kajta, M; Kenis, G; Kubera, M; Maes, M; Scharpe, S | 1 |
| Talley, NJ | 1 |
| Bateman, DN; Chick, J; Good, AM; Kelly, CA; Masterton, G | 1 |
| Carella, A; Cheok, A; Ginovart, N; Houle, S; Hussey, D; Meyer, JH; Potter, WZ; Sagrati, S; Spencer, EP; Wilson, AA | 1 |
| Norman, TR; Olver, JS | 1 |
| Hemrick-Luecke, SK; Iyengar, S; Simmons, RM; Webster, AA; Xu, JY | 1 |
| Azen, SP; Chou, CP; James Gauderman, W; Leuchter, AF; Marie-Mitchell, A | 1 |
| Casciano, R; Chen, J; Geissler, EC; Mallick, R; Panish, JM; Trivedi, MH; Wan, GJ | 1 |
| Dziedzicka-Wasylewska, M; Filip, M; Inan, SY; Przegaliński, E; Wydra, K | 1 |
| Huande, L; Juan, H; Zhiling, Z | 1 |
| Hill, D; Mines, D; Novelli, L; Yu, H | 1 |
| Egberts, TC | 1 |
| Entsuah, R; Padmanabhan, SK; Shelton, C; Vinall, PE | 1 |
| Cela, R; Garcia-Jares, C; Lamas, JP; Llompart, M; Salgado-Petinal, C | 1 |
| Alici, T; Aygoren, MO; Kayir, H; Saglam, E; Uzbay, IT | 1 |
| Lambert, WE; Maudens, KE; Van Peteghem, CH; Wille, SM | 1 |
| Albertazzi, P | 1 |
| Roose, S; Schatzberg, A | 1 |
| Higuchi, T; Honda, K; Kamijima, K; Kitahara, S; Tanaka, S; Yamada, M | 1 |
| Briggs, SD; Case, M; Corya, SA; Sanger, TM; Tollefson, G; Williamson, D | 1 |
| Kim, YK; Lee, KM | 1 |
| Eckert, L; Lançon, C | 1 |
| Cook, IA; Hunter, AM; Leuchter, AF; Morgan, ML | 1 |
| Eastwood, BJ; Jones, CK; Need, AB; Shannon, HE | 1 |
| Andrews, E; Mines, D; Roskell, N; Rubino, A; Tennis, P; Weich, S | 1 |
| Bremner, JD; Charney, DS; Vermetten, E; Vythilingam, M | 1 |
| Artiges, E; Bragulat, V; Frouin, V; Martinot, JL; Paillère-Martinot, ML; Poline, JB | 1 |
| Correa, H; da Rocha, FF | 1 |
| Connor, K; Davidson, JR; Vaishnavi, S | 1 |
| Dhir, A; Kulkarni, SK | 2 |
| Blakely, RD; Deecher, DC; Mahaney, PE; Mason, JN; Richmond, RL; Stack, G; Trybulski, E; Winneker, RC | 1 |
| Ahmed, S; Dunlop, BW; Dunner, DL; Ferguson, JM; Friedman, ES; Gelenberg, AJ; Hirschfeld, RM; Keller, MB; Kocsis, JH; Kornstein, SG; Nemeroff, CB; Ninan, PT; Pedersen, R; Rothschild, AJ; Schatzberg, AF; Schmidt, M; Shelton, RC; Thase, ME; Trivedi, MH; Yan, B; Zajecka, JM | 1 |
| Ahmed, S; Dunner, DL; Ferguson, JM; Friedman, ES; Gelenberg, AJ; Hirschfeld, RM; Keller, MB; Kocsis, JH; Kornstein, SG; Musgnung, J; Nemeroff, CB; Ninan, PT; Pedersen, RD; Rothschild, AJ; Schatzberg, AF; Shelton, RC; Thase, ME; Trivedi, MH; Yan, B; Zajecka, JM | 1 |
| Benattia, I; Demitrack, M; Entsuah, R; Nemeroff, CB; Sloan, DM; Thase, ME | 1 |
| Hay-Schmidt, A; Larsen, MH; Mikkelsen, JD; Rønn, LC | 1 |
| Bramness, JG; Engeland, A; Furu, K | 1 |
| Busto, G; Di Spigno, D; Falcini, R; Salvati, L; Tundo, A | 1 |
| Spindler, PE | 1 |
| Borah, M; Radhakrishnan, M; Ramamoorthy, R | 1 |
| Jürgens, TP; Koch, HJ; Leinisch, E | 1 |
| Chen, MC; Lane, HY; Lin, CH; Lin, CY; Lin, KS | 1 |
| Abebe, K; Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; DeBar, L; Emslie, G; Hughes, C; Iyengar, S; Keller, M; Kennard, B; Leonard, H; McCracken, J; Melhem, N; Onorato, M; Porta, G; Ritz, L; Ryan, N; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Wagner, KD; Zelazny, J | 1 |
| Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH | 1 |
| Kornstein, SG | 1 |
| Hinrichs, JW; Loovers, HM; Scholten, B; van der Weide, J | 1 |
| Kelly, BD | 1 |
| Katona, C | 1 |
| Buitelaar, JK; Roobol, TH | 1 |
| Berlanga, C; Estrada-Camarena, E; Fernández-Guasti, A; Rivera, NM | 1 |
| Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K | 1 |
| Bunchapattanasakda, C; Kongsakon, R | 1 |
| Ahmed, S; Dunlop, BW; Friedman, ES; Keller, M; Kocsis, JH; Kornstein, SG; Li, T; Ninan, PT; Pedersen, R; Thase, M; Yan, B | 1 |
| Vitiello, B | 1 |
| Cook, IA; Hunter, AM; Leuchter, AF; Ravikumar, S | 1 |
| Aslan, E; Başterzi, AD; Delialioğlu, N; Taşdelen, B; Tot Acar, S; Yazici, A; Yazici, K | 1 |
| Diaz-Rojas, J; Einarson, TR; Jaramillo, LE; Lopera, MM; Machado, M | 1 |
| Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; DeBar, L; Emslie, G; Iyengar, S; Keller, M; Kennard, B; Leonard, H; Mayes, T; McCracken, J; Porta, G; Ritz, L; Ryan, N; Shamseddeen, W; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Wagner, KD | 1 |
| Díaz, A; Pazos, A; Rodríguez-Gaztelumendi, A; Rojo, ML | 1 |
| Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J | 1 |
| Entsuah, R; Nemeroff, CB; Sheehan, DV; Thase, ME | 1 |
| Burslem, K; Greenstreet, L; Knight, C; Lenox-Smith, A | 1 |
| Campbell, GM; Case, M; Corya, SA; Henley, DB; Osuntokun, O; Thase, ME; Trivedi, MH; Watson, SB | 1 |
| Curcio, R; Nicoli, R; Rudaz, S; Veuthey, JL | 1 |
| Anderson, GM; Fontenot, MB; McFatter, RM; Musso, MW | 1 |
| Cook, IA; Hunter, AM; Korb, AS; Leuchter, AF | 2 |
| Cook, IA; Hunter, AM; Leuchter, AF; Muthén, BO | 1 |
| Barrio, RJ; Goicolea, MA; Gómez-Caballero, A; Sánchez, A; Ugarte, A; Unceta, N | 1 |
| Dunlop, BW; Dunner, DL; Friedman, ES; Gelenberg, A; Goldstein, C; Holland, P; Keller, MB; Kocsis, JH; Kornstein, SG; Pedersen, R; Rothschild, AJ; Shelton, R; Thase, ME; Trivedi, MH; Zajecka, JM | 1 |
| Brent, DA | 1 |
| Başterzi, AD; Buturak, V; Cimen, B; Eskandari, G; Taşdelen, B; Tot Acar, S; Yazici, A; Yazici, K | 1 |
| Bergeron, R; Blier, P; Hébert, C; Laberge, L; Tremblay, P; Ward, HE | 1 |
| Baumer, C; Koren, G; O'Brien, L; Sachs, H; Thieme, D | 1 |
| Desmarais, JE; Looper, KJ | 1 |
| Drummer, OH; Gerostamoulos, D; Pilgrim, JL | 1 |
| Rush, AJ | 1 |
| Dunlop, BW; Friedman, ES; Keller, M; Kornstein, SG; Li, T; Ninan, P; Pedersen, R; Rothschild, AJ | 1 |
| Abrams, M; Cook, IA; Hunter, AM; Leuchter, AF | 1 |
| Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; DeBar, L; Emslie, GJ; Iyengar, S; Keller, M; Kennard, B; Mayes, T; McCracken, J; Onorato, M; Porta, G; Ryan, N; Spirito, A; Strober, M; Vitiello, B; Wagner, KD; Zelazny, J | 1 |
| Agius, M; Gardner, J; Liu, K; Zaman, R | 1 |
| Erden, F; Gacar, N; Göçmez, SS; Ulak, G; Utkan, T | 1 |
| Chang, HH; Chen, PS; Chi, MH; Gean, PW; Lee, IH; Lee, SY; Lu, RB; Yang, YK | 1 |
| Gelenberg, A; Keller, M; Kocsis, JH; Kornstein, SG; Li, T; Ninan, P; Pedersen, R; Thase, ME; Trivedi, MH | 1 |
| Chang, HH; Chen, PS; Chi, MH; Gean, PW; Lu, RB; Wang, HC; Yang, YK; Yeh, TL | 1 |
| Cook, IA; Hunter, AM; Leuchter, AF | 2 |
| Kourti, PV; Samanidou, VF | 1 |
| Fisar, Z; Hroudová, J; Raboch, J | 1 |
| Goldsmith, L; Moncrieff, J | 1 |
| Bartell, SE; Furlong, ET; Logue, A; Painter, MM; Schoenfuss, HL; Schultz, MM; Werner, SL | 1 |
| Beste, J; Blackwell, JC; Patel, BN | 1 |
| Joshi, PP; Klaper, RD; Thomas, MA | 1 |
| Cuestas, E; Cuestas, ME | 1 |
| Davidson, RJ; Heller, AS; Johnstone, T; Kalin, NH; Kolden, GG; Light, SN; Peterson, MJ | 2 |
| Alanis, LR; Grégio, AM; Lima, AA; Machado, MÂ; Mattioli, TM; Silva, Sd | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, G; Emslie, GJ; Keller, MB; Porta, G; Ryan, N; Shamseddeen, W; Wagner, KD | 1 |
| Brown, CH; Davis, J; Gibbons, RD; Hur, K; Mann, JJ | 1 |
| Dahmen, N; Engel, A; Gerbaulet, M; Hiemke, C | 1 |
| Brown, CH; Davis, JM; Gibbons, RD; Hur, K; Mann, JJ | 3 |
| Cui, J; Du, GH; Gao, XX; Li, ZF; Li, ZY; Liu, XJ; Qin, XM; Sun, HF; Zhang, LZ; Zhou, YZ | 1 |
| Rittmannsberger, H; Werl, R | 1 |
| Carlini, VP; Chavan, RA; de Barioglio, SR; de Cuneo, MF; Ponzio, MF; Poretti, MB; Rask-Andersen, M; Sawant, RS; Schiöth, HB | 1 |
| Abbas, G; Dar, A; Naqvi, S | 1 |
| Girbig, D; Igl, BW; Lehmann, T; Obendorf, M; Patchev, VK; Prelle, K | 1 |
| Kovatsi, L; Livanos, A; Njau, S; Pantazidou, K; Samanidou, V | 1 |
| Bleich, S; Frieling, H; Herbst, D; Nedeljkov, V; Nedeljkov-Jancic, R; Pavlovic, D; Ribback, S; Wendt, M | 1 |
| Klaper, RD; Thomas, MA | 1 |
| Delagrange, P; Elizalde, N; García-García, AL; Tordera, RM; Venzala, E | 1 |
| Charoenphandhu, J; Charoenphandhu, N; Krishnamra, N; Lapmanee, S; Teerapornpuntakit, J | 1 |
| Choi, YH; Cui, J; Du, GH; Gao, XX; Li, ZY; Qin, XM; Tan, XJ; Tian, JS; Xing, J; Zheng, XY; Zhou, YZ | 1 |
| Barbui, C; Cipriani, A; Furukawa, TA; Koesters, M; Nosè, M; Omori, IM; Purgato, M; Trespidi, C | 1 |
| Humpston, CS; Robinson, ES; Wood, CM | 1 |
| Healy, D; Jureidini, J; Purssey, R; Spielmans, GI | 1 |
| Carroll, BJ | 1 |
| Dorries, KM; Dunner, DL; Gelenberg, AJ; Ninan, PT; Pedersen, R; Rothschild, AJ | 1 |
| Alén, F; de Fonseca, FR; de Heras, RG; Gorriti, MÁ; Orio, L; Pozo, MÁ; Ramírez-López, MT | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, GN; Emslie, GJ; He, J; Hilton, RC; Keller, MB; Mansoor, B; Mayes, T; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Wagner, KD | 1 |
| Chang, HH; Chen, PS; Chi, MH; Gean, PW; Lee, IH; Lu, RB; Tsai, HC; Yang, YK | 1 |
| Charoenphandhu, J; Charoenphandhu, N; Lapmanee, S | 1 |
| Chua, EW; Foulds, J; Kennedy, MA; Miller, AL | 1 |
| Birmaher, B; Brent, D; Clarke, G; Emslie, GJ; He, J; Hilton, R; Mansoor, B; Mayes, TL; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Spirito, A; Wagner, KD | 1 |
| Charlier, P; Falissard, B; Maria, AS; Millet, B; Naudet, F; Reymann, JM | 1 |
| Miller, MC | 1 |
| Davidson, RJ; Heller, AS; Johnstone, T; Kalin, NH; Kolden, GG; Peterson, MJ | 1 |
| Holland, PJ; Keller, MB; Kornstein, SG; Nemeroff, CB; Ninan, PT; Pedersen, RD; Rothschild, AJ; Thase, ME; Trivedi, MH | 1 |
| Cavender, HM; Cooke, JD; Grover, LM; Lima, HK | 1 |
| Makuch, W; Mika, J; Przewlocka, B; Rojewska, E; Zychowska, M | 1 |
| Bury, TB; Dworkin-Brodsky, AD; Fong, PP; Jasion, CM; Kell, RC | 1 |
| Gray, VC; Hughes, RN | 1 |
| Banzi, R; Cusi, C; Moja, L; Randazzo, C; Sterzi, R; Tedesco, D | 1 |
| Croarkin, PE; Mills, JA; Strawn, JR; Suresh, V | 1 |
| Boyce, P; Chen, R; Feng, L; Hu, Y; Shi, H; Wang, G; Wang, X; Xiao, L; Yang, R; Zhou, J; Zhu, X | 1 |
38 review(s) available for cyclohexanol and fluoxetine
| Article | Year |
|---|---|
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Design; Drug Tolerance; Drugs, Investigational; Fluoxetine; Humans; Imipramine; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1995 |
Pharmacologic treatment of rapid ejaculation.
Topics: 1-Naphthylamine; Adult; Clinical Trials as Topic; Clomipramine; Cyclohexanols; Dose-Response Relationship, Drug; Ejaculation; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Venlafaxine Hydrochloride | 1995 |
The role of venlafaxine in rational antidepressant therapy.
Topics: Age Factors; Aged; Ambulatory Care; Animals; Antidepressive Agents; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Hospitalization; Humans; Male; Rats; Receptors, Neurotransmitter; Venlafaxine Hydrochloride | 1994 |
Drug treatment of depression in the 1990s. An overview of achievements and future possibilities.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1996 |
Antidepressant discontinuation: a review of the literature.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Incidence; Monoamine Oxidase Inhibitors; Paroxetine; Recurrence; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Syndrome; Venlafaxine Hydrochloride | 1997 |
Newer antidepressants and the discontinuation syndrome.
Topics: Adverse Drug Reaction Reporting Systems; Cyclohexanols; Dizziness; Fluoxetine; Headache; Humans; Incidence; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sleep Stages; Substance Withdrawal Syndrome; Syndrome; Venlafaxine Hydrochloride | 1997 |
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
Topics: 1-Naphthylamine; Adolescent; Adult; Child; Clinical Trials as Topic; Cyclohexanols; Dizziness; Female; Fluoxetine; Fluvoxamine; Headache; Humans; Infant; Infant, Newborn; Male; MEDLINE; Mental Disorders; Middle Aged; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensation Disorders; Sertraline; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 1997 |
Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.
Topics: 1-Naphthylamine; Antidepressive Agents; Cyclohexanols; Cytochrome P-450 Enzyme System; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 1997 |
The use of newer antidepressants for panic disorder.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Benzodiazepines; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 1997 |
Psychopharmacology of ADHD: children and adolescents.
Topics: Adolescent; Age Factors; Amphetamines; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Cyclohexanols; Dextroamphetamine; Drug Administration Schedule; Fluoxetine; Humans; Methylphenidate; Monoamine Oxidase Inhibitors; Pemoline; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1998 |
Pharmacokinetic interactions of antidepressants.
Topics: Antidepressive Agents; Cyclohexanols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Fluvoxamine; Humans; Mixed Function Oxygenases; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1998 |
Treatment of major depression: is improvement enough?
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Psychiatric Status Rating Scales; Psychometrics; Risk Factors; Secondary Prevention; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
The patient with comorbid depression and anxiety: the unmet need.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Clinical Trials as Topic; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Fluoxetine; Humans; Placebos; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
[Therapeutic action lag time and resistance to treatment].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Diagnosis, Differential; Dibenzocycloheptenes; Drug Resistance; Fluoxetine; Hospitalization; Humans; Severity of Illness Index; Time Factors; Venlafaxine Hydrochloride | 1999 |
Antidepressant treatment of the depressed patient with insomnia.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 1999 |
Pharmacoeconomic studies of antidepressants: focus on venlafaxine.
Topics: Antidepressive Agents, Second-Generation; Buspirone; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclohexanols; Depressive Disorder; Drug Tolerance; Fluoxetine; Fluvoxamine; Humans; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2000 |
Psychopharmacologic treatment of adolescent depression.
Topics: Adolescent; Child; Cyclohexanols; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2001 |
Evidence of early onset of antidepressant effect in randomized controlled trials.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder; Drug Administration Schedule; Fluoxetine; Humans; Mianserin; Mirtazapine; Personality Inventory; Placebos; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Do some antidepressants work faster than others?
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Venlafaxine extended-release: a review of its use in the management of major depression.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Interactions; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |
Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride | 2002 |
Antidepressant monotherapy for bipolar type II major depression.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Bipolar Disorder; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Male; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2003 |
A hot flash on tamoxifen metabolism.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cyclohexanols; Cytochrome P-450 CYP2D6; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Fluoxetine; Hot Flashes; Humans; Hydroxylation; Paroxetine; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Venlafaxine Hydrochloride | 2003 |
New formulations of existing antidepressants: advantages in the management of depression.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Chemistry, Pharmaceutical; Cyclohexanols; Delayed-Action Preparations; Depression; Drug Evaluation; Fluoxetine; Humans; Mianserin; Mirtazapine; Molecular Conformation; Venlafaxine Hydrochloride | 2004 |
Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
Topics: Citalopram; Cyclohexanols; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Mianserin; Mirtazapine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Trazodone; Venlafaxine Hydrochloride | 2006 |
Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Regression Analysis; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2008 |
[A clinical challenge. Pragmatic treatment of migraine and concomitant depression].
Topics: Amitriptyline; Analgesics, Non-Narcotic; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antiemetics; Arrhythmias, Cardiac; Cross-Over Studies; Cyclohexanols; Depression; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Fluoxetine; Humans; Migraine Disorders; Polypharmacy; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride | 2008 |
Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.
Topics: Adult; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Dizziness; Double-Blind Method; Female; Fluoxetine; Gastrointestinal Diseases; Headache; Humans; Hypertension; Male; Middle Aged; Respiratory Tract Infections; Secondary Prevention; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
New antidepressants for older people: a critical review of the evidence base.
Topics: Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; Fluoxetine; Humans; Patient Care Team; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2008 |
Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme System; Depressive Disorder; Drug Interactions; Female; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Tamoxifen; Venlafaxine Hydrochloride | 2009 |
Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.
Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide; Venlafaxine Hydrochloride | 2012 |
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.
Topics: Adolescent; Adult; Aged; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
Duloxetine versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Desvenlafaxine Succinate; Dibenzothiazepines; Duloxetine Hydrochloride; Fluoxetine; Humans; Paroxetine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Thiophenes; Venlafaxine Hydrochloride | 2012 |
Which placebo to cure depression? A thought-provoking network meta-analysis.
Topics: Antidepressive Agents; Biomedical Research; Clinical Trials as Topic; Cyclohexanols; Depression; Fluoxetine; Humans; Placebos; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Citalopram; Cyclohexanols; Fluoxetine; Fluvoxamine; Humans; Norepinephrine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Tension-Type Headache; Venlafaxine Hydrochloride | 2015 |
57 trial(s) available for cyclohexanol and fluoxetine
| Article | Year |
|---|---|
A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Hospitalization; Humans; Male; Middle Aged; Personality Inventory; Venlafaxine Hydrochloride | 1994 |
A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Venlafaxine Hydrochloride | 1996 |
Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
Topics: Ambulatory Care; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Fluoxetine; Humans; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 1998 |
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Middle Aged; Placebos; Prospective Studies; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
Topics: Chromatography, High Pressure Liquid; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Fluoxetine; Humans; Isoenzymes; Paroxetine; Phenotype; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2000 |
A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study.
Topics: Adolescent; Adult; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Personality Inventory; Venlafaxine Hydrochloride | 1999 |
Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dysthymic Disorder; Female; Fluoxetine; Humans; Immune Tolerance; Lymphocyte Activation; Male; Middle Aged; Paroxetine; Personality Inventory; Sertraline; Venlafaxine Hydrochloride | 2000 |
Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Hospitalization; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Recurrence; Venlafaxine Hydrochloride | 2000 |
Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Cytochrome P-450 CYP2D6; Dextromethorphan; Dextrorphan; Drug Interactions; Female; Fluoxetine; Humans; Male; Metabolic Clearance Rate; Phenotype; Selective Serotonin Reuptake Inhibitors; Time Factors; Urinalysis; Venlafaxine Hydrochloride | 2001 |
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Topics: Adult; Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Placebos; Prospective Studies; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Genotype; Humans; Male; Middle Aged; Polymorphism, Genetic; Receptors, Serotonin; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Changes in brain function of depressed subjects during treatment with placebo.
Topics: Adult; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Placebo Effect; Venlafaxine Hydrochloride | 2002 |
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Cytochrome P-450 CYP2D6; Dopamine Uptake Inhibitors; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Early changes in prefrontal activity characterize clinical responders to antidepressants.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Prefrontal Cortex; Single-Blind Method; Venlafaxine Hydrochloride | 2002 |
Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Belgium; Cyclohexanols; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2002 |
Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.
Topics: Administration, Oral; Adult; Alprazolam; Area Under Curve; Breath Tests; Carbon Radioisotopes; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Delayed-Action Preparations; Drug Administration Schedule; Erythromycin; Fluoxetine; Half-Life; Humans; Male; Middle Aged; Molecular Probes; Piperazines; Sertraline; Triazoles; Venlafaxine Hydrochloride | 2004 |
Predictors of improved mood over time in clinical trials for major depression.
Topics: Adult; Affect; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2004 |
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Placebos; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
Topics: Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Cyclohexanols; Demography; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2006 |
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
Topics: Benzodiazepines; Brief Psychiatric Rating Scale; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Mass Screening; Middle Aged; Olanzapine; Prospective Studies; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Refusal; Venlafaxine Hydrochloride | 2006 |
The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interleukin-12; Male; Middle Aged; Paroxetine; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
Topics: Adult; Biomarkers; Brain; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Placebos; Prefrontal Cortex; Psychiatric Status Rating Scales; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Theta Rhythm; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Secondary Prevention; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Dizziness; Double-Blind Method; Female; Fluoxetine; Gastrointestinal Diseases; Headache; Humans; Hypertension; Male; Middle Aged; Respiratory Tract Infections; Secondary Prevention; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment | 2008 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Piperazines; Quinolones; Sertraline; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult | 2010 |
Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Recurrence; Risk Assessment; Time Factors; Treatment Failure; Venlafaxine Hydrochloride | 2008 |
Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression.
Topics: Brain; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Venlafaxine Hydrochloride | 2009 |
Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Biomarkers; Brain-Derived Neurotrophic Factor; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Male; Neurotransmitter Uptake Inhibitors; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sex Characteristics; Venlafaxine Hydrochloride | 2009 |
Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Personality Inventory; Prognosis; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2009 |
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross-Sectional Studies; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Suicide; Suicide, Attempted; Venlafaxine Hydrochloride | 2009 |
Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.
Topics: Adult; Antidepressive Agents; Blood Pressure; Constipation; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dizziness; Double-Blind Method; Female; Fluoxetine; Heart Rate; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Statistics as Topic; Venlafaxine Hydrochloride; Xerostomia | 2009 |
Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Biomarkers; Brain Mapping; Cerebral Cortex; Cyclohexanols; Depression; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Gyrus Cinguli; Humans; Male; Middle Aged; Theta Rhythm; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2009 |
Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.
Topics: Antidepressive Agents; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Numerical Analysis, Computer-Assisted; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.
Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Tachyphylaxis; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Antigens, CD; Cyclohexanols; Depressive Disorder, Major; Female; Flow Cytometry; Fluoxetine; Humans; Lymphocyte Subsets; Male; Statistics, Nonparametric; Venlafaxine Hydrochloride; Young Adult | 2010 |
Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
Topics: Adult; Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Personality Inventory; Psychometrics; Secondary Prevention; Venlafaxine Hydrochloride | 2010 |
Correlation between patient and clinician assessments of depression severity in the PREVENT study.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Psychiatric Status Rating Scales; Severity of Illness Index; Statistics as Topic; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Brain; California; Causality; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Humans; Male; Mood Disorders; Psychiatric Status Rating Scales; Severity of Illness Index; Suicide; Venlafaxine Hydrochloride | 2010 |
Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Male; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Failure; Venlafaxine Hydrochloride | 2010 |
Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder.
Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Neuropsychological Tests; Pharmacogenetics; Polymorphism, Single Nucleotide; Taiwan; Venlafaxine Hydrochloride | 2010 |
TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients.
Topics: Adult; Asian People; Case-Control Studies; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Gene Frequency; Genotype; Humans; Male; Middle Aged; Polymorphism, Genetic; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Taiwan; Treatment Outcome; Tryptophan Hydroxylase; Venlafaxine Hydrochloride; Young Adult | 2011 |
Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Fluoxetine; Follow-Up Studies; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Psychiatric Status Rating Scales; Theta Rhythm; Venlafaxine Hydrochloride | 2011 |
Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder.
Topics: Adult; Anhedonia; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Emotions; Female; Fluoxetine; Follow-Up Studies; Functional Laterality; Humans; Image Processing, Computer-Assisted; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Prefrontal Cortex; Psychiatric Status Rating Scales; Pupil; Surveys and Questionnaires; Venlafaxine Hydrochloride; Young Adult | 2011 |
Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Drug Interactions; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sleep Wake Disorders; Trazodone; Treatment Outcome; Venlafaxine Hydrochloride | 2012 |
Does prior antidepressant treatment of major depression impact brain function during current treatment?
Topics: Adult; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Los Angeles; Male; Middle Aged; Neurons; Prefrontal Cortex; Psychiatric Status Rating Scales; Self Report; Single-Blind Method; Theta Rhythm; Venlafaxine Hydrochloride | 2012 |
Relationships between changes in sustained fronto-striatal connectivity and positive affect in major depression resulting from antidepressant treatment.
Topics: Affect; Antidepressive Agents; Biological Availability; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluoxetine; Frontal Lobe; Humans; Magnetic Resonance Imaging; Male; Nerve Net; Nucleus Accumbens; Psychiatric Status Rating Scales; Reward; Sickness Impact Profile; Treatment Outcome; Venlafaxine Hydrochloride; Visual Cortex | 2013 |
Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Psychometrics; Secondary Prevention; Sexual Dysfunction, Physiological; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult | 2013 |
Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Anxiety; Attention Deficit and Disruptive Behavior Disorders; Behavioral Symptoms; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Fluoxetine; Humans; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
The change of insulin levels after six weeks antidepressant use in drug-naïve major depressive patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Mass Index; Case-Control Studies; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Risk; Severity of Illness Index; Venlafaxine Hydrochloride; Young Adult | 2013 |
The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Body Mass Index; Child; Citalopram; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depression; Depressive Disorder, Major; Double-Blind Method; Emotions; Fluoxetine; Functional Neuroimaging; Humans; Prefrontal Cortex; Venlafaxine Hydrochloride | 2013 |
Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Menopause; Middle Aged; Placebos; Proportional Hazards Models; Recurrence; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
Topics: Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Postmenopause; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Treatment Outcome; Venlafaxine Hydrochloride | 2021 |
127 other study(ies) available for cyclohexanol and fluoxetine
| Article | Year |
|---|---|
Serotonin reuptake inhibitors in Raynaud's phenomenon.
Topics: 1-Naphthylamine; Adult; Aged; Cyclohexanols; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Raynaud Disease; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 1995 |
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Paroxetine; Piperazines; Recurrence; Serotonin Agents; Substance-Related Disorders; Triazoles; Venlafaxine Hydrochloride | 1996 |
Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cyclohexanols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Desipramine; Fluoxetine; Fluvoxamine; Frozen Sections; Humans; Hydroxylation; Imipramine; In Vitro Techniques; Lethal Dose 50; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Venlafaxine Hydrochloride | 1997 |
Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy.
Topics: Adult; Antidepressive Agents; Clonazepam; Cyclohexanols; Depressive Disorder; Desipramine; Drug Therapy, Combination; Female; Fluoxetine; Humans; Hypotension; Panic Disorder; Piperazines; Substance Withdrawal Syndrome; Triazoles; Venlafaxine Hydrochloride | 1997 |
Venlafaxine-fluoxetine-nortriptyline interaction.
Topics: Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Nortriptyline; Venlafaxine Hydrochloride | 1997 |
Erythromelalgia: response to serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Cyclohexanols; Erythromelalgia; Female; Fluoxetine; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 1997 |
Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.
Topics: Animals; Cyclobutanes; Cyclohexanols; Eating; Fenfluramine; Fluoxetine; Male; Neurotransmitter Uptake Inhibitors; Obesity; Rats; Rats, Sprague-Dawley; Venlafaxine Hydrochloride | 1997 |
Severe anticholinergic side effects with venlafaxine-fluoxetine combination.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Receptors, Cholinergic; Venlafaxine Hydrochloride | 1997 |
Breast enlargement during chronic antidepressant therapy.
Topics: Breast; Breast Diseases; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Hyperplasia; Male; Menopause; Paroxetine; Prolactin; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride; Weight Gain | 1997 |
Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.
Topics: Adult; Cyclohexanols; Depressive Disorder; Drug Interactions; Female; Fluoxetine; Humans; Panic Disorder; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride | 1998 |
Re: Severe anticholinergic side effects with venlafaxine-fluoxetine combination.
Topics: Cholinergic Antagonists; Cyclohexanols; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Receptors, Adrenergic; Receptors, Cholinergic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1998 |
Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.
Topics: Animals; Antidepressive Agents, Second-Generation; Binding, Competitive; Brain; Carrier Proteins; Cyclohexanols; Fluoxetine; Imipramine; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neurotransmitter Uptake Inhibitors; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Radioligand Assay; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Symporters; Venlafaxine Hydrochloride | 1998 |
Potentiation of the time-dependent, antidepressant-induced changes in the agonistic behaviour of resident rats by the 5-HT1A receptor antagonist, WAY-100635.
Topics: Agonistic Behavior; Animals; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzodiazepines; Central Nervous System Depressants; Cyclohexanols; Drug Implants; Drug Synergism; Ethanol; Fluoxetine; Interpersonal Relations; Male; Piperazines; Pyridines; Rats; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Antagonists; Time Factors; Venlafaxine Hydrochloride | 1997 |
Venlafaxine-fluoxetine interaction.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cholinergic Antagonists; Cyclohexanols; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology.
Topics: Animals; Blood Pressure; Cyclohexanols; Electric Conductivity; Electrophysiology; Fluoxetine; In Vitro Techniques; Male; Membrane Potentials; Muscle, Smooth, Vascular; Patch-Clamp Techniques; Phentermine; Potassium Channel Blockers; Potassium Channels; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
Venlafaxine: new preparation. Just another antidepressant.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Evaluation; Fluoxetine; Humans; Imipramine; Meta-Analysis as Topic | 1998 |
Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Birth Weight; Body Weight; Cyclohexanols; Female; Fluoxetine; Growth; Male; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Venlafaxine Hydrochloride; Weight Gain | 1999 |
Comparing the efficacy and safety of fluoxetine and venlafaxine in outpatient depression.
Topics: Ambulatory Care; Clinical Trials as Topic; Cyclohexanols; Drug Administration Schedule; Fluoxetine; Humans; Peer Review, Research; Research Design; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Dystonia as a side effect of nonneuroleptics.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cyclohexanols; Drug Interactions; Dystonia; Fluoxetine; Guanfacine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted; Venlafaxine Hydrochloride | 1999 |
[Proofs of efficacy].
Topics: Antidepressive Agents, Tricyclic; Clomipramine; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Drug; Fluoxetine; Humans; Norepinephrine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
Venlafaxine versus fluoxetine.
Topics: Cyclohexanols; Depressive Disorder; Drug Administration Schedule; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Research Design; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety.
Topics: Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Fluoxetine; Humans; Neurotransmitter Uptake Inhibitors; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Defense mechanisms and personality in depression.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Defense Mechanisms; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Patient Dropouts; Personality Disorders; Predictive Value of Tests; Psychiatric Status Rating Scales; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 1999 |
Effect of acute treatment with YM992 on extracellular serotonin levels in the rat frontal cortex.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Cerebral Cortex; Citalopram; Cyclohexanols; Dose-Response Relationship, Drug; Extracellular Space; Fluorobenzenes; Fluoxetine; Frontal Lobe; Male; Morpholines; p-Chloroamphetamine; Piperidines; Rats; Rats, Wistar; Serotonin; Serotonin Agents; Serotonin Antagonists; Synaptosomes; Tritium; Venlafaxine Hydrochloride | 2000 |
Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Citalopram; Cyclohexanols; Dose-Response Relationship, Drug; Extracellular Space; Fluorobenzenes; Fluoxetine; Frontal Lobe; Male; Morpholines; Norepinephrine; Piperidines; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Venlafaxine Hydrochloride | 2000 |
Newer antidepressants: a comparison of tolerability in general practice.
Topics: Adult; Aged; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder; Family Practice; Female; Fluoxetine; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1999 |
Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study.
Topics: Animals; Antidepressive Agents; Autoradiography; Brain Chemistry; Carrier Proteins; Citalopram; Cyclohexanols; Desipramine; Fluoxetine; Gene Expression Regulation; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Norepinephrine Plasma Membrane Transport Proteins; Organ Specificity; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Stereotaxic Techniques; Symporters; Trimipramine; Venlafaxine Hydrochloride | 2001 |
Do antidepressants affect motivation in conditioned place preference?
Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Cocaine; Conditioning, Psychological; Cyclobutanes; Cyclohexanols; Dose-Response Relationship, Drug; Fluoxetine; Male; Motivation; Norepinephrine; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2000 |
Fluoxetine (Sarafem) for premenstrual dysphoric disorder.
Topics: Adult; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Nausea; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride; Weight Gain | 2001 |
Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio.
Topics: 5-Hydroxytryptophan; Adult; Analysis of Variance; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Imipramine; Interferon-gamma; Interleukin-10; Male; Middle Aged; Venlafaxine Hydrochloride | 2001 |
Prefrontal changes and treatment response prediction in depression.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder, Major; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Prefrontal Cortex; Sertraline; Venlafaxine Hydrochloride | 2001 |
Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus.
Topics: Animals; Antidepressive Agents, Second-Generation; Corticosterone; Cyclohexanols; Fluoxetine; Gene Expression; Hippocampus; Male; Maze Learning; Memory; Rats; Rats, Inbred Strains; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; RNA, Messenger; Venlafaxine Hydrochloride | 2001 |
Successful use of cardiac allograft from serotonin antagonist intoxication.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Fluoxetine; Gastrointestinal Diseases; Heart Transplantation; Humans; Male; Postoperative Complications; Serotonin Antagonists; Suicide; Transplantation, Homologous; Venlafaxine Hydrochloride | 2001 |
Once-daily venlafaxine extended release (XR) vs. fluoxetine for the treatment of depression.
Topics: Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Fluoxetine; Half-Life; Humans; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats.
Topics: Acetic Acid; Administration, Intravesical; Adrenergic Uptake Inhibitors; Animals; Cats; Cyclohexanols; Duloxetine Hydrochloride; Electromyography; Female; Fluoxetine; Humans; Methiothepin; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Thiophenes; Urethra; Urinary Bladder; Venlafaxine Hydrochloride | 2002 |
Treating hot flashes with drugs: an update.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents, Second-Generation; Antihypertensive Agents; Clonidine; Cyclohexanecarboxylic Acids; Cyclohexanols; Female; Fluoxetine; Gabapentin; gamma-Aminobutyric Acid; Hot Flashes; Humans; Venlafaxine Hydrochloride | 2002 |
The brain tells: early signs of depression recovery.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Prefrontal Cortex; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Venlafaxine Hydrochloride | 2002 |
Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Fluoxetine; Male; Microdialysis; Norepinephrine; Paroxetine; Piperazines; Prefrontal Cortex; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Venlafaxine Hydrochloride | 2002 |
Effects of 5-HT(6) receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Desipramine; Drug Synergism; Extracellular Space; Fluoxetine; Glutamic Acid; Male; Microdialysis; Neurons; Norepinephrine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Sulfonamides; Synaptic Transmission; Thiophenes; Venlafaxine Hydrochloride | 2003 |
Infinite enantiomeric resolution of basic compounds using highly sulfated cyclodextrin as chiral selector in capillary electrophoresis.
Topics: Cyclodextrins; Cyclohexanols; Electrophoresis, Capillary; Fluoxetine; Mass Spectrometry; Methadone; Stereoisomerism; Tramadol; Venlafaxine Hydrochloride | 2003 |
Acute and continuation treatment adequacy with venlafaxine extended release compared with fluoxetine.
Topics: California; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Follow-Up Studies; Humans; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Stimulatory effect of antidepressants on the production of IL-6.
Topics: 5-Hydroxytryptophan; Adult; Age Factors; Aging; Antidepressive Agents; Blood Cells; Cyclohexanols; Depressive Disorder; Drug Combinations; Female; Fluoxetine; Humans; Imipramine; In Vitro Techniques; Inflammation; Interleukin-6; Male; Middle Aged; Tumor Necrosis Factor-alpha; Venlafaxine Hydrochloride | 2004 |
SSRIs in IBS: sensing a dash of disappointment.
Topics: Antidepressive Agents; Cyclohexanols; Fluoxetine; Humans; Inflammatory Bowel Diseases; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2003 |
Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Doxepin; Drug Overdose; Drug Prescriptions; Emergency Service, Hospital; Female; Fluoxetine; Humans; Imipramine; Information Services; Male; Mianserin; Mirtazapine; Paroxetine; Patient Admission; Patient Readmission; Poison Control Centers; Retrospective Studies; Risk Assessment; Scotland; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sertraline; Trazodone; Venlafaxine Hydrochloride | 2004 |
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
Topics: Adult; Benzylamines; Carbon Radioisotopes; Carrier Proteins; Citalopram; Corpus Striatum; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sertraline; Tomography, Emission-Computed; Venlafaxine Hydrochloride | 2004 |
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cyclohexanols; Cyclopropanes; Disease Models, Animal; Drug Therapy, Combination; Duloxetine Hydrochloride; Fluoxetine; Formaldehyde; Gabapentin; gamma-Aminobutyric Acid; Male; Methyltyrosines; Milnacipran; Neuromuscular Junction; Norepinephrine; p-Chloroamphetamine; Pain; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Thiophenes; Venlafaxine Hydrochloride | 2004 |
Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Topics: Activities of Daily Living; Acute Disease; Ambulatory Care; Cost-Benefit Analysis; Cyclohexanols; Decision Support Techniques; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Costs; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Opioid and monoamine systems mediate the discriminative stimulus of tramadol in rats.
Topics: Adrenergic Uptake Inhibitors; Analgesics, Opioid; Animals; Antidepressive Agents; Biogenic Monoamines; Conditioning, Operant; Cyclohexanols; Cyclopropanes; Discrimination, Psychological; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Male; Milnacipran; Morphine; Morpholines; Naloxone; Narcotic Antagonists; Nomifensine; Rats; Rats, Wistar; Reboxetine; Receptors, Opioid, mu; Selective Serotonin Reuptake Inhibitors; Sodium Chloride; Tramadol; Venlafaxine Hydrochloride | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; Drug Therapy; Fluoxetine; Humans; Paroxetine; Patient Satisfaction; Primary Health Care; Psychiatry; Psychology; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Social Work | 2004 |
Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI).
Topics: Antidepressive Agents, Tricyclic; Chromatography, High Pressure Liquid; Citalopram; Cyclohexanols; Depression; Female; Fluoxetine; Humans; Male; Paroxetine; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Venlafaxine Hydrochloride | 2005 |
Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Child; Citalopram; Cohort Studies; Cyclohexanols; Databases, Factual; Female; Fluoxetine; Hospitalization; Humans; Male; Middle Aged; Prevalence; Risk Factors; Sex Factors; Suicide, Attempted; Time Factors; United Kingdom; Venlafaxine Hydrochloride | 2005 |
Causal or casual?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Drug Overdose; Fluoxetine; Humans; Risk Factors; Suicide, Attempted; Venlafaxine Hydrochloride | 2005 |
Rapid screening of selective serotonin re-uptake inhibitors in urine samples using solid-phase microextraction gas chromatography-mass spectrometry.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Fluoxetine; Fluvoxamine; Gas Chromatography-Mass Spectrometry; Humans; Mianserin; Mirtazapine; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sertraline; Solid Phase Microextraction; Venlafaxine Hydrochloride | 2005 |
Discriminative stimulus properties of tianeptine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Caffeine; Central Nervous System Stimulants; Conditioning, Operant; Cyclohexanols; Discrimination Learning; Discrimination, Psychological; Fluoxetine; Male; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Thiazepines; Venlafaxine Hydrochloride | 2006 |
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Desvenlafaxine Succinate; Fluoxetine; Gas Chromatography-Mass Spectrometry; Humans; Mianserin; Microchemistry; Mirtazapine; Piperazines; Reproducibility of Results; Sertraline | 2005 |
Induction of neuroserpin expression in rat frontal cortex after chronic antidepressant treatment and electroconvulsive treatment.
Topics: Animals; Antidepressive Agents; Cyclohexanols; Electroconvulsive Therapy; Expressed Sequence Tags; Fluoxetine; Frontal Lobe; Imipramine; Male; Neuropeptides; Neuroserpin; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; RNA, Messenger; Serpins; Sertraline; Venlafaxine Hydrochloride | 2006 |
Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Chemistry; Carrageenan; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Duloxetine Hydrochloride; Edema; Fluoxetine; Hot Temperature; Hyperalgesia; Male; Norepinephrine; Paroxetine; Pressure; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Thiophenes; Venlafaxine Hydrochloride | 2006 |
Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Cohort Studies; Cyclohexanols; Dothiepin; Fluoxetine; Humans; Incidence; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Suicide; Venlafaxine Hydrochloride | 2007 |
Effects of antidepressant treatment on neural correlates of emotional and neutral declarative verbal memory in depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Emotions; Female; Fluoxetine; Frontal Lobe; Gyrus Cinguli; Humans; Male; Mental Recall; Middle Aged; Paired-Associate Learning; Personality Inventory; Positron-Emission Tomography; Semantics; Sertraline; Venlafaxine Hydrochloride; Wechsler Scales | 2007 |
Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis.
Topics: Adult; Affect; Biogenic Monoamines; Brain Stem; Caudate Nucleus; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Disruptive, Impulse Control, and Conduct Disorders; Female; Fluorodeoxyglucose F18; Fluoxetine; Gyrus Cinguli; Hippocampus; Humans; Hypothalamus; Magnetic Resonance Imaging; Male; Nucleus Accumbens; Positron-Emission Tomography; Psychomotor Disorders; Putamen; Radiopharmaceuticals; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Venlafaxine Hydrochloride | 2007 |
Was the exacerbation of PTSD symptoms after high doses of venlafaxine due to the noradrenergic mechanism? A case report.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Female; Fluoxetine; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Venlafaxine Hydrochloride | 2007 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Kava; Mianserin; Mirtazapine; Paroxetine; Psychometrics; Sertraline; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2007 |
Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents, Second-Generation; Cyclohexanols; Dose-Response Relationship, Drug; Fluoxetine; Male; Mice; Motor Activity; Receptors, Adrenergic, alpha-2; Selective Serotonin Reuptake Inhibitors; Serotonin; Swimming; Venlafaxine Hydrochloride; Yohimbine | 2007 |
Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter.
Topics: Binding Sites; Binding, Competitive; Blotting, Western; Cells, Cultured; Cocaine; Cyclohexanols; Desvenlafaxine Succinate; Fluoxetine; Humans; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Radioligand Assay | 2007 |
Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclohexanols; Dentate Gyrus; Fluoxetine; GAP-43 Protein; Hippocampus; Imipramine; Male; Neuronal Plasticity; Neurotransmitter Uptake Inhibitors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Synaptophysin; Time Factors; Transcription, Genetic; Venlafaxine Hydrochloride | 2008 |
[Use of antidepressants among children and adolescents--did the warnings lead to fewer prescriptions?].
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Child; Cyclohexanols; Drug Prescriptions; Drug Utilization; Female; Fluoxetine; Humans; Male; Risk Factors; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2007 |
Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Topics: Adult; Citalopram; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Demography; Drug Resistance; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
[Palinopsia following discontinuation of venlafaxine].
Topics: Adult; Afterimage; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoxetine; Humans; Perceptual Disorders; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride; Visual Perception | 2008 |
Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Behavior, Animal; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Exploratory Behavior; Fluoxetine; Hindlimb Suspension; Male; Maze Learning; Mice; Motor Activity; Olfactory Bulb; Ondansetron; Paroxetine; Rats; Rats, Wistar; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Stress, Psychological; Venlafaxine Hydrochloride | 2008 |
Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine.
Topics: Adult; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Fluoxetine; Hospitalization; Humans; Interview, Psychological; Male; Mood Disorders; Patient Readmission; Prevalence; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires; Time Factors; Tobacco Use Disorder; Venlafaxine Hydrochloride | 2008 |
Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics.
Topics: Adolescent; Adult; Aged; Alleles; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cyclohexanols; Cytochrome P-450 CYP2D6; Fluoxetine; Gene Dosage; Gene Frequency; Genotype; Humans; Middle Aged; Models, Genetic; Phenotype; Polymorphism, Genetic; Predictive Value of Tests; Psychotropic Drugs; Risperidone; Venlafaxine Hydrochloride; Young Adult | 2008 |
Do new-generation antidepressants work?
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Piperazines; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2008 |
Flat dose-response curves for efficacy: what do they mean to the clinician?
Topics: Attitude of Health Personnel; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluoxetine; Humans; Neurotransmitter Uptake Inhibitors; Paroxetine; Physicians; Randomized Controlled Trials as Topic; Sertraline; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
[A place for SSRIs in the treatment of severely depressed children and adolescents].
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide; Venlafaxine Hydrochloride | 2008 |
Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Cyclohexanols; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Immobility Response, Tonic; Locomotion; Male; Mice; Receptors, Adrenergic, alpha-2; Risperidone; Swimming; Venlafaxine Hydrochloride; Yohimbine | 2008 |
Reduction in the latency of action of antidepressants by 17 beta-estradiol in the forced swimming test.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Cyclohexanols; Desipramine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estradiol; Estrogens; Female; Fluoxetine; Injections, Subcutaneous; Motor Activity; Ovariectomy; Rats; Rats, Wistar; Reaction Time; Selective Serotonin Reuptake Inhibitors; Swimming; Venlafaxine Hydrochloride | 2008 |
The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Decision Support Techniques; Depressive Disorder, Major; Economics, Pharmaceutical; Fluoxetine; Focus Groups; Humans; Models, Theoretical; Psychometrics; Selective Serotonin Reuptake Inhibitors; Thailand; Venlafaxine Hydrochloride | 2008 |
Recent NIMH clinical trials and implications for practice.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Child, Preschool; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Fluoxetine; Humans; Mental Disorders; Methylphenidate; Multicenter Studies as Topic; National Institute of Mental Health (U.S.); Obsessive-Compulsive Disorder; Psychotropic Drugs; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2008 |
Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia.
Topics: Amitriptyline; Antidepressive Agents; Colombia; Convulsive Therapy; Cost-Benefit Analysis; Cyclohexanols; Decision Trees; Depressive Disorder; Developing Countries; Drug Costs; Female; Fluoxetine; Health Expenditures; Hospitalization; Humans; Male; Models, Theoretical; Monte Carlo Method; National Health Programs; Office Visits; Psychotherapy; Venlafaxine Hydrochloride | 2008 |
Altered CB receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Autoradiography; Cyclohexanols; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Administration Schedule; Exploratory Behavior; Fluoxetine; Guanosine 5'-O-(3-Thiotriphosphate); Immunosuppressive Agents; Isotopes; Male; Olfactory Bulb; Prefrontal Cortex; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Signal Transduction; Time Factors | 2009 |
Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Cyclohexanols; Decision Trees; Delphi Technique; Depressive Disorder, Major; Drug Costs; Drugs, Generic; Fluoxetine; Humans; Psychiatric Status Rating Scales; Quality-Adjusted Life Years; Treatment Outcome; United Kingdom; Venlafaxine Hydrochloride | 2009 |
An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Nortriptyline; Olanzapine; Personality Inventory; Psychometrics; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Development of an in-capillary approach to nanoscale automated in vitro cytochromes p450 assays.
Topics: Autoanalysis; Chromatography, High Pressure Liquid; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Fluoxetine; Humans; Isoenzymes; Mass Spectrometry; Pharmaceutical Preparations; Quinidine; Recombinant Proteins; Solutions; Venlafaxine Hydrochloride | 2009 |
Dose-finding study of fluoxetine and venlafaxine for the treatment of self-injurious and stereotypic behavior in rhesus macaques (Macaca mulatta).
Topics: Administration, Oral; Animals; Behavior, Animal; Blood Platelets; Cyclohexanols; Dose-Response Relationship, Drug; Fluoxetine; Hydroxyindoleacetic Acid; Macaca mulatta; Male; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Serotonin; Stereotyped Behavior; Venlafaxine Hydrochloride | 2009 |
Development of a stir bar sorptive extraction based HPLC-FLD method for the quantification of serotonin reuptake inhibitors in plasma, urine and brain tissue samples.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Chromatography, High Pressure Liquid; Citalopram; Cyclohexanols; Fluorescence; Fluoxetine; Humans; Male; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2010 |
The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
Topics: Adolescent; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Fluoxetine; Humans; Male; Multicenter Studies as Topic; Paroxetine; Personality Assessment; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Suicide, Attempted; Venlafaxine Hydrochloride | 2009 |
Agomelatine: new drug. Adverse effects and no proven efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexanols; Depression; Depressive Disorder; Double-Blind Method; Drug Approval; Europe; Fluoxetine; Humans; Hypnotics and Sedatives; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptors, Melatonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Changes in antidepressant metabolism in pregnancy evidenced by metabolic ratios in hair: a novel approach.
Topics: Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Female; Fluoxetine; Gas Chromatography-Mass Spectrometry; Hair; Humans; Postpartum Period; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Third; Sertraline; Venlafaxine Hydrochloride | 2010 |
Deaths involving serotonergic drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Australia; Cause of Death; Citalopram; Cyclohexanols; Female; Fluoxetine; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Serotonin Agents; Sertraline; Tramadol; Venlafaxine Hydrochloride | 2010 |
Combining antidepressant medications: a good idea?
Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Fluoxetine; Humans; Mianserin; Mirtazapine; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2010 |
An audit to compare discharge rates between antidepressant monotherapies prescribed for pure unipolar depression versus depression in the presence of other indications.
Topics: Adult; Antidepressive Agents; Citalopram; Community Mental Health Centers; Comorbidity; Cyclohexanols; Depressive Disorder; England; Fluoxetine; Guideline Adherence; Humans; Medical Audit; Mianserin; Mirtazapine; Patient Discharge; Practice Patterns, Physicians'; Sertraline; Suicide; Suicide Prevention; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Effects of long-term treatment with fluoxetine and venlafaxine on rat isolated vas deferens.
Topics: Adenosine Triphosphate; Animals; Antidepressive Agents, Second-Generation; Cyclohexanols; Electric Stimulation; Fluoxetine; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth; Norepinephrine; Potassium Chloride; Rats; Rats, Wistar; Serotonin; Time Factors; Vas Deferens; Venlafaxine Hydrochloride | 2010 |
Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Delivery Systems; Female; Fluoxetine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult | 2011 |
Rapid HPLC method for the simultaneous monitoring of duloxetine, venlaflaxine, fluoxetine and paroxetine in biofluids.
Topics: Chromatography, High Pressure Liquid; Cyclohexanols; Duloxetine Hydrochloride; Fluoxetine; Humans; Limit of Detection; Paroxetine; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Thiophenes; Venlafaxine Hydrochloride | 2009 |
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride | 2010 |
The psychoactive effects of antidepressants and their association with suicidality.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Emotions; Female; Fluoxetine; Humans; Internet; Male; Middle Aged; Prevalence; Suicidal Ideation; Venlafaxine Hydrochloride; Young Adult | 2011 |
Selective uptake and biological consequences of environmentally relevant antidepressant pharmaceutical exposures on male fathead minnows.
Topics: Animals; Antidepressive Agents; Brain; Bupropion; Cyclohexanols; Cyprinidae; Endocrine Disruptors; Female; Fluoxetine; Male; Reproduction; Sertraline; Testis; Venlafaxine Hydrochloride; Vitellogenins; Water Pollutants, Chemical | 2011 |
Antidepressant use during pregnancy. FPIN’s clinical inquiries.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Evidence-Based Medicine; Female; Fluoxetine; Humans; Odds Ratio; Paroxetine; Physicians, Family; Pregnancy; Pregnancy Complications; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2011 |
Gene-class analysis of expression patterns induced by psychoactive pharmaceutical exposure in fathead minnow (Pimephales promelas) indicates induction of neuronal systems.
Topics: Animals; Behavior, Animal; Brain; Carbamazepine; Cyclohexanols; Cyprinidae; Female; Fluoxetine; Gene Expression Profiling; Gene Expression Regulation; Male; Oligonucleotide Array Sequence Analysis; Psychotropic Drugs; Reverse Transcriptase Polymerase Chain Reaction; Venlafaxine Hydrochloride | 2012 |
[Approximate entropy of the placebo effect in clinical trials of newer antidepressants].
Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Placebo Effect; Placebos; Severity of Illness Index; Venlafaxine Hydrochloride | 2010 |
The effects of antidepressants and pilocarpine on rat parotid glands: an immunohistochemical study.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Calcium-Binding Proteins; Calponins; Cell Proliferation; Cyclohexanols; Epithelial Cells; Fluoxetine; Male; Microfilament Proteins; Muscarinic Agonists; Parotid Gland; Pilocarpine; Proliferating Cell Nuclear Antigen; Random Allocation; Rats; Rats, Wistar; Time Factors; Venlafaxine Hydrochloride | 2011 |
High venlafaxine serum levels after prior fluoxetine medication.
Topics: Antidepressive Agents, Second-Generation; Cholinergic Antagonists; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2012 |
Anti-depressant effects of Xiaoyaosan on rat model of chronic unpredictable mild stress: a plasma metabonomics study based on NMR spectroscopy.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biomarkers; Chronic Disease; Cyclohexanols; Depression; Disease Models, Animal; Drugs, Chinese Herbal; Fluoxetine; Magnetic Resonance Spectroscopy; Male; Metabolomics; Motor Activity; Multivariate Analysis; Rats; Rats, Sprague-Dawley; Stress, Psychological; Sucrose; Venlafaxine Hydrochloride | 2012 |
Does aripiprazole protect from serotonin syndrome?
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Tremor; Venlafaxine Hydrochloride; Young Adult | 2012 |
Differential effects of fluoxetine and venlafaxine on memory recognition: possible mechanisms of action.
Topics: Animals; Brain; Cyclohexanols; Fluoxetine; Gene Expression; Male; MAP Kinase Signaling System; Mice; Nitric Oxide Synthase Type I; Receptor, trkB; Receptors, AMPA; Recognition, Psychology; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Venlafaxine Hydrochloride | 2012 |
Comparison of monoamine reuptake inhibitors for the immobility time and serotonin levels in the hippocampus and plasma of sub-chronically forced swim stressed rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Cyclohexanols; Fluoxetine; Hippocampus; Imipramine; Immobilization; Male; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Stress, Psychological; Swimming; Venlafaxine Hydrochloride | 2012 |
Endpoints of drug discovery for menopausal vasomotor symptoms: interpretation of data from a proxy of disease.
Topics: Acetamides; Amines; Animals; Body Temperature Regulation; Cyclohexanecarboxylic Acids; Cyclohexanols; Disease Models, Animal; Diurnal Enuresis; Drug Discovery; Estradiol; Female; Fluoxetine; Gabapentin; gamma-Aminobutyric Acid; Hot Flashes; Hypnotics and Sedatives; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Skin Temperature; Venlafaxine Hydrochloride | 2012 |
A simple HPLC method for the simultaneous determination of two selective serotonin reuptake inhibitors and two serotonin-norepinephrine reuptake inhibitors in hair, nail clippings, and cerebrospinal fluid.
Topics: Adrenergic Uptake Inhibitors; Biological Transport; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; Cyclohexanols; Duloxetine Hydrochloride; Fluoxetine; Hair; Humans; Nails; Norepinephrine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Venlafaxine Hydrochloride | 2012 |
Effects of amitriptyline, fluoxetine, tranylcypromine and venlafaxine on rat vascular smooth muscle in vitro--the role of the endothelium.
Topics: Amitriptyline; Animals; Antidepressive Agents; Aorta, Abdominal; Aorta, Thoracic; Cyclic AMP; Cyclic GMP; Cyclohexanols; Dinoprost; Endothelium, Vascular; Fluoxetine; In Vitro Techniques; Muscle Contraction; Muscle, Smooth; Nitric Oxide; Phenylephrine; Potassium Channel Blockers; Potassium Chloride; Rats; Rats, Inbred Lew; Selective Serotonin Reuptake Inhibitors; Tranylcypromine; Venlafaxine Hydrochloride | 2012 |
Psychoactive pharmaceuticals induce fish gene expression profiles associated with human idiopathic autism.
Topics: Animals; Autistic Disorder; Carbamazepine; Cell Adhesion Molecules; Cyclohexanols; Cyprinidae; Fluoxetine; Gene Expression Profiling; Gene Expression Regulation; Humans; Microarray Analysis; Nerve Tissue Proteins; Psychotropic Drugs; Receptors, Immunologic; Venlafaxine Hydrochloride; Water Pollutants, Chemical | 2012 |
Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cyclohexanols; Depression; Depressive Disorder; Disease Models, Animal; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Risk Factors; RNA, Messenger; Social Behavior; Stress, Psychological; Thiazepines; Venlafaxine Hydrochloride; Vesicular Glutamate Transport Protein 1 | 2012 |
Duodenal calcium transporter mRNA expression in stressed male rats treated with diazepam, fluoxetine, reboxetine, or venlafaxine.
Topics: Animals; Calcium; Calcium Channels; Cyclohexanols; Diazepam; Duodenum; Fluoxetine; Gene Expression Regulation; Ion Transport; Male; Morpholines; Rats; Reboxetine; Restraint, Physical; RNA, Messenger; Venlafaxine Hydrochloride | 2012 |
An investigation of the antidepressant action of xiaoyaosan in rats using ultra performance liquid chromatography-mass spectrometry combined with metabonomics.
Topics: Animals; Antidepressive Agents; Benzoates; Biomarkers; Bridged-Ring Compounds; Catechin; Chalcone; Chromatography, Liquid; Citric Acid; Citric Acid Cycle; Coumaric Acids; Creatine Kinase; Creatinine; Cyclohexanols; Drugs, Chinese Herbal; Flavanones; Fluoxetine; Gallic Acid; Gastrointestinal Tract; Glucosides; Glycine; Hippurates; Ketoglutaric Acids; Kynurenic Acid; Male; Mass Spectrometry; Metabolic Networks and Pathways; Metabolomics; Microbiota; Monoterpenes; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley; Stress, Psychological; Tryptophan; Tyrosine; Venlafaxine Hydrochloride | 2013 |
Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task.
Topics: Acetamides; Adrenergic alpha-2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Choice Behavior; Cyclobutanes; Cyclohexanols; Fluoxetine; Hypnotics and Sedatives; Idazoxan; Impulsive Behavior; Male; Norepinephrine; Paroxetine; Rats; Reaction Time; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2013 |
Inappropriate data and measures lead to questionable conclusions.
Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide | 2013 |
Inappropriate data and measures lead to questionable conclusions--reply.
Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide | 2013 |
Suicide risk and efficacy of antidepressant drugs.
Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide | 2013 |
Suicide risk and efficacy of antidepressant drugs--reply.
Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide | 2013 |
Increased alcohol consumption in rats after subchronic antidepressant treatment.
Topics: Alcohol Drinking; Alcohols; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Addictive; Body Weight; Conditioning, Operant; Cyclohexanols; Disease Models, Animal; Fluoxetine; Male; Motor Activity; Rats; Rats, Wistar; Self Administration; Time Factors; Venlafaxine Hydrochloride | 2013 |
Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Cyclohexanols; Depression; Disease Models, Animal; Fluoxetine; Food Preferences; Male; Maze Learning; Morpholines; Physical Conditioning, Animal; Rats; Rats, Wistar; Reboxetine; Restraint, Physical; Running; Stress, Psychological; Sucrose; Swimming; Venlafaxine Hydrochloride | 2013 |
Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Base Sequence; Cyclohexanols; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Haplotypes; Humans; Molecular Sequence Data; Nortriptyline; Polymorphism, Genetic; Sequence Analysis, DNA; Venlafaxine Hydrochloride; Young Adult | 2013 |
When depression doesn't lead with depression.
Topics: Anger; Bipolar Disorder; Cyclohexanols; Depression; Depressive Disorder, Major; Emotions; Female; Fluoxetine; Humans; Irritable Mood; Male; Mood Disorders; Prefrontal Cortex; Venlafaxine Hydrochloride | 2013 |
Antidepressants that inhibit both serotonin and norepinephrine reuptake impair long-term potentiation in hippocampus.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclohexanols; Fluoxetine; Hippocampus; Imipramine; Long-Term Potentiation; Male; Maprotiline; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Serotonin; Synaptic Transmission; Venlafaxine Hydrochloride | 2014 |
The influence of microglia activation on the efficacy of amitriptyline, doxepin, milnacipran, venlafaxine and fluoxetine in a rat model of neuropathic pain.
Topics: Amitriptyline; Animals; Antidepressive Agents; Calcium-Binding Proteins; Cyclohexanols; Cyclopropanes; Doxepin; Fluoxetine; Ganglia, Spinal; Hyperalgesia; Male; Microfilament Proteins; Microglia; Milnacipran; Neuralgia; Rats, Wistar; Sciatic Nerve; Spinal Cord; Treatment Outcome; Venlafaxine Hydrochloride | 2015 |
The antidepressants venlafaxine ("Effexor") and fluoxetine ("Prozac") produce different effects on locomotion in two species of marine snail, the oyster drill (Urosalpinx cinerea) and the starsnail (Lithopoma americanum).
Topics: Animals; Antidepressive Agents; Cyclohexanols; Fluoxetine; Locomotion; Snails; Species Specificity; Venlafaxine Hydrochloride; Water Pollutants, Chemical | 2015 |
Drug-, dose- and sex-dependent effects of chronic fluoxetine, reboxetine and venlafaxine on open-field behavior and spatial memory in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Cyclohexanols; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Fluoxetine; Locomotion; Male; Maze Learning; Memory, Short-Term; Morpholines; Motor Activity; Rats; Rats, Inbred Strains; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sex Factors; Spatial Memory; Time Factors; Venlafaxine Hydrochloride | 2015 |
What next? A Bayesian hierarchical modeling re-examination of treatments for adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Bayes Theorem; Cyclohexanols; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2020 |